MDWD
MediWound Ltd.
MDWD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MDWD overall, supported by stronger fundamentals and stronger modeled upside.
MDWD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
MDWD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDWD PE Valuation
MDWD has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MDWD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MDWD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MDWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.60 | +$1.04 |
| Q1 2026 | -$2.26 | -$0.17 |
| Q4 2025 | -$2.10 | +$0.97 |
| Q3 2025 | -$1.90 | +$1.00 |
| Q2 2025 | -$2.64 | -$0.48 |
| Q1 2025 | -$2.09 | -$0.71 |
| Q4 2024 | -$3.07 | -$2.30 |
| Q3 2024 | -$2.90 | -$1.14 |
MDWD is still losing money, but far less than before: $1.60 per share over the past year, against $3.85 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MDWD on earnings quality, reporting a profit while its opponent remains loss making.
MDWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.1M | -46% |
| Q1 2026 | $1.5M | -63% |
| Q4 2025 | $1.9M | -68% |
| Q3 2025 | $5.4M | +25% |
| Q2 2025 | $5.7M | +13% |
| Q1 2025 | $4M | -20% |
| Q4 2024 | $5.8M | +9.4% |
| Q3 2024 | $4.4M | -8.8% |
MDWD's revenue has slid since its 2022 peak: $3M last quarter, down 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -306% | -206 points |
| Q1 2026 | -541% | -409 points |
| Q4 2025 | -418% | -314 points |
| Q3 2025 | -120% | -3.5 points |
| Q2 2025 | -100% | -12 points |
| Q1 2025 | -132% | -57 points |
| Q4 2024 | -104% | -31 points |
| Q3 2024 | -117% | -53 points |
MDWD's operating margin was −306% last quarter, down 206 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MDWD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MDWD on profitability, with a higher operating margin.
MDWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.1M | -$3.3M |
| Q1 2026 | -$8.6M | -$3.5M |
| Q4 2025 | -$5.5M | -$3M |
| Q3 2025 | -$4.3M | +$664K |
| Q2 2025 | -$6.8M | -$166K |
| Q1 2025 | -$5.1M | +$193K |
| Q4 2024 | -$2.4M | +$2.4M |
| Q3 2024 | -$4.9M | -$12K |
MDWD has burned cash in almost every quarter: −$28M over the past year, against −$19M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MDWD on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.8K shares |
| 1 year | +19% | +2M shares |
| 3 years | +40% | +3.7M shares |
| 5 years | +231% | +9M shares |
| Available history | +232% | +9M shares |
MDWD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $747,000 |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
MDWD spent $747,000 buying back its own shares over the past year, after none the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MDWD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -11.2x | Net Cash |
| Q4 2023 | -2.1x | Net Cash |
| Q1 2020 | -1.1x | Net Cash |
| Q4 2019 | -1.3x | Net Cash |
| Q3 2019 | -0.5x | Net Cash |
MDWD has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MDWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 59.4 | Neutral |
MDWD's weekly RSI is 44 (neutral) and its Stochastic is 59 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MDWD PE vs Healthcare Sector
| Metric | MDWD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MDWD has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MDWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.0 | 0.5% below |
| 20 week MA | $13.5 | 4.1% below |
| 50 week MA | $15.5 | 17% below |
| 100 week MA | $16.9 | 23% below |
| 200 week MA | $15.1 | 14% below |
MDWD is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MDWD on trend strength, trading above more of its moving averages.
MDWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.1 | $28.6 | +35% |
| 2021 | $28.6 | $15.8 | -45% |
| 2022 | $15.8 | $11.5 | -27% |
| 2023 | $11.5 | $10.2 | -12% |
| 2024 | $10.2 | $17.7 | +74% |
| 2025 | $17.7 | $18.8 | +6.2% |
| 2026 YTD | $18.8 | $13.0 | -31% |
MDWD has finished lower in three of the last six years. It's down 31% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MDWD on returns for 2026, with the stronger performance.